Fit to ScaleGet Series A-ready

Fit to Scale · GTM for founder-led B2B SaaS

Build the GTM evidence investors expect before Series A.

Investors don't fund traction. They fund repeatable traction.

A few founder-closed logos won't carry a Series A. The question in the room is whether the motion repeats without you. Fit to Scale turns scattered wins into the evidence of repeatability — clear ICP, conversion logic, and a handover story — that a Series A demands.

Get Series A-ready

Traction that doesn't yet prove repeatability.

  • Your wins are real but founder-closed — hard to attribute to a system.
  • You can't show a clean ICP and a repeatable conversion path.
  • Metrics tell a story you can't fully defend in diligence.
  • 'How does this scale without you?' has no crisp answer.

Series A is a repeatability test, not a traction test.

By Series A, the bar moves from 'can you sell this?' to 'can this be sold by a system?'. Wins that depend on founder vision, trust and network read as risk, not proof — because none of those three scale with capital.

The work is to convert your traction into evidence: a defined ICP, a conversion logic that holds, and a credible founder-to-team handover.

The evidence we assemble.

Anchored to the six levers, framed as diligence-ready proof:

01

ICP & positioning

A defensible target, not 'everyone'.

02

MVP & clear use case

The outcome that repeats across customers.

03

Business case & value proposition

ROI that holds outside your pitch.

04

Qualification

A pipeline an investor can trust.

05

Pricing logic

Monetisation that scales.

06

Sales narrative

A motion that survives the founder leaving the call.

Aligning the system first is what unlocked €2.5M of new investment in one case and a full, converting pipeline in another — the exact signals a Series A looks for.

CS-IAI / SaaS / Media

Situation. Post-crisis team running three products across B2C and B2B; founder-driven, opportunistic sales; no clear ICP or value proposition.

Move. We defined a sharp ICP, shut down the B2C line, and merged two products into one focused offering.

Result. €2.5M new investment secured, merger with a competitor, €2M pipeline generated, €600K ARR closed.

CS-IISaaS / Health Tech

Situation. Founder-led selling proved strong demand, but the hired sales team couldn't convert — active pipeline, no closes, no structure or tracking.

Move. We located the pipeline breakpoints, rebuilt the sales narrative around clear ROI, and installed structured targets and tracking.

Result. From zero to multiple closed deals in 3 months; a full, progressing pipeline.

How we fix it

The 10-week program produces both the system and the evidence of it. You walk into fundraising able to show repeatability, not just revenue. If the GTM isn't ready to raise on, I'll tell you directly.

How we rebuild the system — six-block Fit to Scale program over 10 weeks

This is not sales theater.

We do not promise:

  • fully AI-automated pipelines
  • hypergrowth or '10x scaling'
  • guaranteed revenue
  • We can't guarantee a round — only readiness.

We deliver:

  • GTM clarity
  • market-fit direction and alignment
  • an executable, scalable GTM system fit to your product and industry

The goal is not to look scalable — the goal is to become scalable.

Start with clarity.

The 10-week Fit-to-Scale program is not a pitch call. It's a structured analysis of where your pipeline breaks, a layout of how to fix the misalignment, and a system to scale sales. If there's no fit, I'll tell you directly.

Get Series A-ready
Dr. Denis Jung, founder of Fit to Scale

I'll show you where your pipeline breaks — and how to fix it.

Dr. Denis Jung

Founder, Fit to Scale

Fix the Pipeline

One more thing

Raising in the next 6–12 months?

A short breakdown of the GTM evidence investors actually probe — and how to prepare it.

Get Series A-ready